FY2025 EPS Estimates for Cytosorbents Raised by Analyst

Cytosorbents Co. (NASDAQ:CTSO) – HC Wainwright lifted their FY2025 earnings per share estimates for Cytosorbents in a note issued to investors on Thursday, May 15th. HC Wainwright analyst S. Lee now anticipates that the medical research company will post earnings per share of ($0.19) for the year, up from their prior estimate of ($0.24). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.14) EPS, FY2028 earnings at ($0.10) EPS and FY2029 earnings at ($0.09) EPS.

CTSO has been the topic of several other reports. StockNews.com assumed coverage on shares of Cytosorbents in a research report on Tuesday, May 13th. They issued a “hold” rating on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Thursday.

Cytosorbents Trading Up 7.8%

NASDAQ CTSO opened at $0.90 on Monday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The stock’s 50-day moving average is $1.00 and its 200-day moving average is $0.99. The firm has a market cap of $56.35 million, a P/E ratio of -2.50 and a beta of 1.17.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $8.73 million during the quarter, compared to analysts’ expectations of $9.01 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTSO. Millennium Management LLC bought a new position in Cytosorbents in the fourth quarter valued at approximately $30,000. Goldman Sachs Group Inc. raised its position in Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares in the last quarter. Key Client Fiduciary Advisors LLC lifted its stake in Cytosorbents by 127.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 43,900 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 8,400 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares during the period. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.